EMA Authorised: Denbrayce (denosumab) — Mabxience Research SL

View source ↗

Summary

The EMA has authorised Denbrayce (denosumab) from Mabxience Research SL for the treatment of giant cell tumor of the bone. The product targets bone neoplasms an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Denbrayce (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Mabxience Research SL. Decision date: 29/07/2025